Full history for every metric is available with a Kvantra account
Genomics BioSci & Tech. Co.,Ltd. (4195.TWO)
Key financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | TWD m | 443 | 390 | 419 | 396 | 483 | 708 | 708 |
| Operating profit | TWD m | -84 | -84 | |||||
| Net profit | TWD m | 1 | 19 | 72 | -168 | -223 | -39 | -39 |
| EPS reported | TWD | -0.54 | -0.54 | |||||
| Operating cashflow per share | TWD | -1.20 | -1.20 | |||||
| Capex per share | TWD | 1.13 | 1.13 | |||||
| FCF per share | TWD | -2.33 | -2.33 | |||||
| Free cash flow | TWD m | -169 | -169 | |||||
| Net debt | TWD m | 420 | 429 | |||||
| Book value equity | TWD m | 510 | 510 | |||||
| Book value per share | TWD | 7.04 | 7.04 | |||||
| Number of shares | m | 72.45 | 72.45 | |||||
| DPS (TTM paid) | TWD | 0.00 | 0.00 |
Financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.65 | 4.62 | |||||
| P/S LTM | x | 2.63 | 3.33 | |||||
| P/FCF LTM | x | -11.05 | -13.98 | |||||
| EV/EBITDA LTM | x | -278.38 | -332.23 | |||||
| EV/Sales LTM | x | 3.29 | 3.93 | |||||
| Earnings Yield LTM | % | -2.12% | -1.85% | |||||
| FCF Yield | % | -9.05% | -7.15% | |||||
| Quality | ||||||||
| ROE | % | -7.73% | -7.63% | |||||
| ROIC | % | -6.95% | -6.95% | |||||
| Operating margin | % | -11.88% | -11.88% | |||||
| Gross margin | % | 26.84% | 26.84% | |||||
| FCF/Sales | % | -23.80% | -23.80% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +46.74% | +46.74% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.27 | -0.27 | |||||
| Net Debt/EBITDA | x | -56.27 | -56.27 | |||||
| EBIT/Net interest | x | -5.67 | -5.67 | |||||
| Net debt/market cap | % | 22.55% | 18.21% | |||||
| Net debt/Equity | x | 0.82 | 0.84 | |||||
| Gross debt/equity | x | 1.23 | 1.23 | |||||
Company overview
Genomics BioSci & Tech. Co.,Ltd. specializes in providing a comprehensive array of services within the field of genomic sequencing. Its core offerings encompass standard and intricate DNA sequencing, including TAF-certified options, with clients also benefiting from complimentary sequencing primer and primer walking services. Beyond sequencing, the company is proficient in synthesizing peptides, genes, and oligonucleotides. Furthermore, its analytical capabilities extend to crucial laboratory services such as sample preparation, gene expression analysis, genotyping, DNA methylation analysis, and microbial identification. The firm also delivers advanced sequencing solutions, including genome-level, targeted, gene regulation, and metagenomic sequencing, alongside cutting-edge third-generation sequencing technologies. To support these services, it offers integrated sequencing platforms and streamlined workflows. Additionally, Genomics BioSci & Tech. Co.,Ltd. provides specialized diagnostic screenings, such as non-invasive prenatal testing (NIPT), spinal muscular atrophy (SMA) carrier screening, and fragile X syndrome premutation screening. Established in 2001, the company's headquarters are located in New Taipei City, Taiwan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Genomics BioSci & Tech. Co.,Ltd. (4195.TWO)
Genomics BioSci & Tech. Co.,Ltd. specializes in providing a comprehensive array of services within the field of genomic sequencing. Its core offerings encompass standard and intricate DNA sequencing, including TAF-certified options, with clients also benefiting from complimentary sequencing primer and primer walking services. Beyond sequencing, the company is proficient in synthesizing peptides, genes, and oligonucleotides. Furthermore, its analytical capabilities extend to crucial laboratory services such as sample preparation, gene expression analysis, genotyping, DNA methylation analysis, and microbial identification. The firm also delivers advanced sequencing solutions, including genome-level, targeted, gene regulation, and metagenomic sequencing, alongside cutting-edge third-generation sequencing technologies. To support these services, it offers integrated sequencing platforms and streamlined workflows. Additionally, Genomics BioSci & Tech. Co.,Ltd. provides specialized diagnostic screenings, such as non-invasive prenatal testing (NIPT), spinal muscular atrophy (SMA) carrier screening, and fragile X syndrome premutation screening. Established in 2001, the company's headquarters are located in New Taipei City, Taiwan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free